National Pharmaceuticals Corp
PINK SHEETS : NFRM

March 18, 2011 08:05 ET

National Pharmaceuticals Corp. in Association With Globe Labs to Enter Into Discussion on Clinical Trials Protocols for GLB333

MIAMI, FLORIDA--(Marketwire - March 18, 2011) - National Pharmaceuticals Corp. (PINK SHEETS:NFRM) or the "Company" announced today that in conjunction with Globe Laboratories have identified a contract research organization (CRO) from Europe to develop protocols for clinical trials of GLB333. Parties have decided that the Clinical Investigations group from Vienna, Austria would be most suitable for conducting the Phase I clinical trials. The trials which would be the first for GLB333 shall focus on the ability of the drug to speed up wound healing in diabetes patients suffering from chronic wound and tissue efflux.

"We are pleased to have this critical step initiated to identify and potentially engage a strong and experienced CRO group to advise us and conduct the necessary work with our drug for proof of efficacy and performance", said Elaine Affleck, President of National Pharmaceuticals Corp.

About National Pharmaceuticals Corp.

National Pharmaceuticals Corp. is a Pharmaceutical Research and Development Corporation focused on leading edge technologies for treatment of human diseases. The company has embarked into the business of licensing mid stage development drugs for further development and marketing worldwide.

Forward-looking Statements - Important Information about Forward-Looking Statements in this press release is within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to the company or its management, identify forward-looking statements. These statements are based on current expectations, estimates and projections about the company's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above.

Contact Information

  • National Pharmaceuticals Corporation
    Elaine Affleck
    (954) 903-1967